1
Tianbao Lu, Karen L Milkiewicz, Pierre Raboisson, Maxwell David Cummings, Raul R Calvo, Daniel J Parks, Louis V Lafrance III, Juan Jose Marugan Sanchez, Joan Gushue, Kristi Leonard: Substituted 1,4-diazepines and uses thereof. Ortho McNeil Pharmaceutical, Laura Donnelly, October 3, 2006: US07115598 (2 worldwide citation)

The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are defined ...


2
Robert Wells Marquis Jr, Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita: Protease inhibitors. SmithKline Beecham Corporation, SmithKline Beecham, Linda E Hall, Stephen A Venetianer, Charles M Kinzig, July 29, 2008: US07405209 (1 worldwide citation)

The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating ...


3

4
Nalin L Subasinghe, Shelley Ballentine, Jeremy M Travins, Ehab M Khalil, Farah Ali, Kristi A Leonard, Joan M Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings: Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions. Janssen Pharmaceutica, Mary A Appollina, January 11, 2011: US07868023

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are as defined in the spec ...


5
Nalin L Subasinghe, Shelley Ballentine, Jeremy M Travins, Ehab M Khalil, Farah Ali, Kristi A Leonard, Joan M Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings: Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions. Janssen Pharmaceutica, Mary Appollina, June 10, 2008: US07385066

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specifi ...


6

7
Tianbao Lu, Karen L Milkiewicz, Pierre Raboisson, Maxwell David Cummings, Raul R Calvo, Daniel J Parks, Louis V Lafrance, Juan Jose Marugan Sanchez, Joan Gushue, Kristi Leonard: Substituted 1,4-diazepines and uses thereof. Philip S Johnson, Johnson & Johnson, November 4, 2004: US20040220179-A1

The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are define ...


8
Tianbao Lu, Karen L Milkiewicz, Pierre Raboisson, Maxwell David Cummings, Raul R Calvo, Daniel J Parks, Louis V LaFrance, Juan Jose Marugan Sanchez, Joan Gushue, Kristi Leonard: Substituted 1,4-diazepines and uses thereof. Philip S Johnson, Johnson & Johnson, October 19, 2006: US20060235007-A1

The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are defined h ...


9
Nalin L Subasinghe, Shelley Ballentine, Jeremy M Travins, Ehab M Khalil, Farah Ali, Kristi A Leonard, Joan M Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings: Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions. Philip S Johnson, Johnson & Johnson, March 22, 2007: US20070066667-A1

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specif ...


10